您的位置: 首页 > 农业专利 > 详情页

COMBINATION LIPOSOMAL COMPOSITIONS FOR CANCER TREATMENT
专利权人:
МАЛЛИНКРОДТ Эл-Эл-Си (US)
发明人:
ЯНГ Джун (US),ВУ Стивен Х. (US),ХЕРМАН Клифф Дж. (US)
申请号:
RU2014120216/15
公开号:
RU2014120216A
申请日:
2012.10.31
申请国别(地区):
RU
年份:
2015
代理人:
摘要:
1. A method of delivering a therapeutic agent to a subject, comprising: (a) administering to the subject a liposome containing a therapeutic agent; and (b) administering to the subject a lipid nanoparticle containing a nonionic initiating agent; where the release of the therapeutic agent from the liposome after administration of the lipid nanoparticle is increased compared to the release of the therapeutic agent from the liposome without administration of the lipid nanoparticle. 2. The method of claim 1, wherein the liposome contains one or more lipids selected from the group consisting of a phospholipid, steroid, and cationic lipid. The method of claim 2, wherein the phospholipid is selected from phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid. The method of claim 3, wherein the phosphatidylcholine is DSPC.5. The method of claim 3, wherein the phosphatidylglycerol is DSPG. 6. The method of claim 3, wherein the phosphatidylethanolamine is DSPE-PEG (2000). The method of claim 2, wherein the steroid is cholesterol. The method of claim 1, wherein the lipid nanoparticle is selected from the group consisting of a second liposome, micelle, and mixtures thereof. The method of claim 8, wherein the lipid nanoparticle is a second liposome. The method of claim 9, wherein the second liposome contains one or more lipids selected from the group consisting of a phospholipid, steroid, and cationic lipid. The method of claim 10, wherein the phospholipid is selected from phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid. The method of claim 11, wherein the phosphatidylcholine is DPPC. The method of claim 10, wherein the steroid is cholesterol. The method of claim 10, wherein the cationic lipid is DOTAP. The method of claim 1, wherein the non-ionic initiation1. Способ доставки терапевтического агента субъекту, включающий:
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充